HCR 553 Module 5 Quality in Clinical Trials

HCR 553 Module 5 Quality in Clinical Trials

Introduction

Yes! The use of digital pills in clinical trials is a promising innovation. The antipsychotic drug aripiprazole, in combination with an ingestible sensor developed by Proteus Health and Otsuka, illustrates how technology can help solve long-term issues in research. Ensuring that the participants follow the prescription of their medications is one of the main issues of clinical trials. This has an impact on the reliability of data and the reports of drug effectiveness. The digital pills offer a method of real-time ingestion monitoring, enhancing accuracy and the quality of the overall trial.

Clinical Trial Benefits

The pills are particularly applicable in those tests in which compliance is paramount, like the ones on psychiatric disorders. As an illustration, schizophrenia patients tend to fall out of their medication schedules. In this context, non-compliance can be detected by the use of a sensor to monitor medication intake among individuals, which can aid researchers to detect non-compliance at an early stage (Satyamitra et al., 2022). This enables prompt interventions, which potentially enhances participant results and retention levels. The tool complies with the FDA regulations: 21 CFR Part 312, which focuses on proper data collection when investigating drugs.

The digital pills similarly meet 21 CFR Part 11 of the FDA, which promotes the application of electronic records in research. This implies that data gathered through digital ingestion may be stored, checked, and secured under controlled systems (Ogg, 2005). By the use of these records, researchers will not be required to depend on self-reported information, which tends to be erroneous. Digital pills can provide objective data that may contribute to more accurate trial results.

Ethical Considerations

Nevertheless, the ethical issues of these instruments also exist. Informed consent is made more complicated. The participants have to be aware of the fact that they are not only taking a drug but are also under observation. The principle of respect for persons described in the Belmont Report entails informing participants of the nature and purpose of the research (Ogg, 2005). If participants are not told how their data will be used or if they feel coerced, then ethical violations may occur.

Privacy and Autonomy

Privacy is another big issue. Such ingestible sensors should provide information that is protected by systemic safety standards like the Health Insurance Portability and Accountability Act (HIPAA). In the event of creating access to or sharing the information without proper protection, there is a possibility that confidentiality may be breached (Satyamitra et al., 2022). In sensitive experiments, they may not feel relaxed that their consumption of medication is being monitored. This becomes particularly serious when looking into psychiatric patients who might already feel vulnerable.

Digital pill usage is also a question of autonomy. The participants should be the ones to agree to this method of tracking without being locked out of the trial. The subjects have to be, according to the standards of Good Clinical Practice (GCP), treated with dignity and freedom of choice (Meyer, 2020). If digital pills are made mandatory, this may reduce participation or lead to forced consent.

Justice and Equity

The codes, like the Declaration of Helsinki, remind us that in all research, the most important thing is the welfare of the study subject. The use of monitoring equipment should not be transformed into surveillance and punishment. Instead, they would need to be utilized to enforce the health of the individual and protect the integrity of the testing. Moreover, the researchers ought not to be biased in selecting subjects. Once this is available only to particular populations who can either afford or access the technology, the principle of justice associated with the Common Rule (45 CFR 46) is violated (Meyer, 2020). All participants should receive a level playing field to benefit equally without discrimination based on technology access.

Conclusion

Ultimately, the digital pills can enhance data quality and compliance in clinical trials significantly. They give accurate and real-time information that cannot be received through traditional means. However, the success of such innovation depends on how it is carried out. The researchers need to balance the cost and ethical responsibility. Participants are to be informed fully, their information must be secured, and their independence must be respected. With the necessary safeguards, digital pills can form part of the future of clinical research.

References

Meyer, M. N. (2020). There Oughta Be a Law: When Does(n’t) the U.S. Common Rule Apply? The Journal of Law Medicine & Ethics, 48(S1), 60–73. https://doi.org/10.1177/1073110520917030

Ogg, G. (2005). A practical guide to quality management in clinical trial research. CRC

Press.

Satyamitra, M. M., Perez-Horta, Z., DiCarlo, A. L., Cassatt, D. R., Rios, C. I., Price, P. W., & Taliaferro, L. P. (2022). NIH Policies and Regulatory Pathways to U.S. FDA licensure: Strategies to Inform Advancement of Radiation Medical Countermeasures and Biodosimetry Devices. Radiation Research, 197(5). https://doi.org/10.1667/rade-21-00198.1

CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER

 

 

 

HCR 553 Module 5 Quality in Clinical Trials